Third, preclinical models must include immune-competent systems, such as humanized mice or co-cultures of tumor organoids with autologous immune cells, to assess inhibitor effects on immune checkpoint including PD-L1, cytokine secretion, and T/NK cell cytotoxicity [125]. This evidence concerns the gene CD274 and neoplasm.